Dopamine agonists

Handbook of Parkinson's Disease, Fourth Edition

Volumn , Issue , 2007, Pages 335-348

  Street, Valerie ^a   Stacy, Mark ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67449105377     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (59)

1. Factor SA. Dopamine Agonists. Med Clin North Am 1999; 83:415-443.
2. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 2002; 287:1653-1661.
3. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54:93-101.
4. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 2006; 21:343-353.
5. Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging 2001; 18:389-396.
6. Tan EK, Jankovic J. Choosing dopamine agonists in Parkinson's disease. Clin Neu-ropharmacol 2001; 24:247-253.
7. Pierantozzi M, Palmieri MG, Mazzone P, et al. Deep brain stimulation of both subthalamic nucleus and internal globus pallidus restores intracortical inhibition in Parkinson's disease paralleling apomorphine effects: a paired magnetic stimulation study. Clin Neurophysiol 2002; 113:108-113.
8. Koller W, Stacy M. Other formulations and future considerations for apomorphine for subcutaneous injection therapy. Neurology 2004; 62(6 suppl 4):S22-S26.
9. Manson AJ, Hanagasi H, Turner K, et al. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 2001; 124(Pt 2):331-340.
10. Lewitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology 2004; 62(6 suppl 4):S8-S11.
11. Bowron A. Practical considerations in the use of apomorphine injectable. Neurology 2004; 62(6 suppl 4):S32-S36.
12. Poewe W, Wenning GK. Apomorphine: an underutilized therapy for Parkinson's disease. Mov Disord 2000; 15:789-794.
13. Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58:1385-1392.
14. Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 2001; 22:93-94.
15. Pahwa R, Lyons KE. Solving the puzzle of Parkinson's therapy. Practical Neurology 2002; Feb:17-18, 22-24.
16. Goetz CG, Tanner CM, Glantz RH, Klawans HL. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology 1985; 35:749-751.
17. Physician's Desk Reference. 60th ed. Montvale, NJ: Thomson PDR, 2006.
18. Factor SA, Weiner WJ. Viewpoint: Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993; 8:257-262.
19. Clarke CE, Speller JM. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease. Cochrane Database Syst Rev 2000; (2):CD000236.
20. Ramaker C, van Hilten JJ. Bromocriptine versus levodopa in early Parkinson's disease. Cochrane Database Syst Rev 2000; (3):CD002258.
21. van Hilten JJ, Ramaker C, Van de Beek WJ, Finken MJ. Bromocriptine for levodopa-induced motor complications in Parkinson's disease. Cochrane Database Syst Rev 2000; (2):CD001203.
22. Guttman M, International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997; 49:1060-1065.
23. Jankovic J. Long-term study of pergolide in Parkinson's disease. Neurology 1985; 35:296-299.
24. Bonuccelli U, Colzi A, Del Dotto P. Pergolide in the treatment of patients with early and advanced Parkinson's disease. Clin Neuropharmacol 2002; 25:1-10.
25. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995; 45(suppl):S13-S21.
26. Olanow CW, Fahn S, Muenter M, et al. A Multicenter double-blind placebo controlled trial of pergolide as adjunct to Sinemet in the treatment of Parkinson's disease. Mov Disord 1994; 9:40-47.
27. Tintner R, Manian P, Gauthier P, Jankovic J. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol 2005; 62:1290-1295.
28. Waller EA, Kaplan J, Heckman MG. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2005; 80:1016-1020.
29. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995; 18; 338-347.
30. Lieberman AN, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a randomized, placebo-controlled, parallel group study. Neurology 1997; 49:162-168.
31. Parkinson Study Group. Pramipexole vs. levodopa as and initial treatment for Parkinson disease. JAMA 2000; 284:1931-1938.
32. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61:1044-1053.
33. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry. 1999; 66:436-441.
34. Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel; motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52:1908-1910.
35. Stacy M. Sleep disorders in Parkinson's disease: Epidemiology and management. Drugs Aging 2002; 19:733-739.
36. Rissling I, Geller F, Bandmann O, et al. Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks". Mov Disord 2004; 19:1279-1284.
37. Samanta JES, Stacy M. Pathologic Gambling in Parkinson's disease. Mov Disord 1998; 15(suppl 3):111.
38. Gschwandtner U, Astar J, Renard S, Fuhr P. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 2001; 24:170-172.
39. Dodd ML, Kloss KJ, Bower KH, et al. Pathological gambling caused by drugs used to treat Parkinson's disease. Arch Neurol 2005; 62:1-5.
40. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998; 51:1057-1061.
41. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997; 49:393-399.
42. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342:1484-1491.
43. Lang AE, Rascol O, Brooks DJ, et al. The development of dyskinesias in Parkinson's disease patients receiving ropinirole and given supplemental l-dopa. Neurology 2002; 58(suppl 3):A82.
44. Pahwa R, Factor SA, Elmer LW. Ropinirole 24-hour prolonged release reduces awake time spent "off" in patients with Parkinson's disease not optimally controlled with L-dopa. Neurology 2006; 66(suppl 2):A292-A293.
45. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergo-line taken once daily in Parkinson's disease. Neurology 1996; 46:1062-1065.
46. Bracco F, Battaglia A, Chouza C, et al. The long-acting dopamine receptor agonist caber-goline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004; 18:733-746.
47. Clarke CE, Deane KD. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2001; (1):CD001519.
48. Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005; 353:1976-1977.
49. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005; 65(suppl 1):S3-S5.
50. Pfeiffer RF. A promising new technology for Parkinson's disease. Neurology 2005; 65(suppl 1):S6-S10.
51. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch. Neurol. 2003; 60:1721-1728.
52. Watts RL, Wendt RL, Nausieda P. Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early stage, idiopathic Parkinson's disease: a multicenter, multinational, randomized, double-blind, placebo-controlled trial. Mov Disord 2004; 10(suppl 9):S258.
53. LeWitt P, Nausieda P, Chang F-L, et al. Rotigotine transdermal system in a multicenter trial of patients with advanced-stage Parkinson's disease as adjunctive therapy to lev-odopa. Neurology 2006; 66(suppl 2):A184-A185.
54. Simon N, Micallef J, Reynier JC, et al. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmaco-kinetic/pharmacodynamic, randomized, double-blind study. Mov Disord 2005; 20(7):803-809.
55. Castro-Caldas A, Delwaide P, Jost W, et al. The Parkinson-Control study: A 1-year randomized, double-blind trial comparing piribedil (150 mg/d) with bromocriptine (25mg/d) in early combination with levodopa in Parkinson's disease. Mov Disord 2006; 21:500-509.
56. Hanna PA, Ratkos L, Ondo WG, et al. A comparison of the therapeutic efficacy of pergolide and pramipexole in Parkinson's disease. J Neural Transm 2001; 108:63-70.
57. Hauser R, Reider C, Stacy M, et al. Acute vs. gradual pramipexole to ropinirole switch. Mov Disord 1998; 15(suppl):133.
58. Olanow CW, Koller WC. An algorithm for the management of Parkinson's disease. Neurology 1998; 50(suppl):S10-S14.
59. Poewe W. Should treatment of Parkinson's disease be started with a dopamine agonist? Neurology 1998; 51(suppl):S21-S24.